Loading...
XNAS
SWKH
Market cap209mUSD
Dec 04, Last price  
17.14USD
1D
-3.44%
1Q
17.24%
Jan 2017
64.81%
Name

SWK Holdings Corp

Chart & Performance

D1W1MN
XNAS:SWKH chart
P/E
15.50
P/S
4.65
EPS
1.11
Div Yield, %
Shrs. gr., 5y
-0.72%
Rev. gr., 5y
7.91%
Revenues
45m
+19.14%
43,128,00054,030,00060,794,00065,219,00045,258,00000637,0006,447,00017,400,00023,460,00022,380,00037,486,00025,990,00030,747,00036,712,00056,155,00041,484,00037,760,00044,987,000
Net income
13m
-15.10%
-17,966,000-2,426,000-8,021,000-3,655,00034,893,000-707,000-1,066,000-1,421,00012,862,00020,765,000-7,370,00028,888,0003,047,0006,195,00023,828,0005,202,00025,929,00013,491,00015,887,00013,488,000
CFO
23m
+54.83%
-16,263,000-1,661,000-8,433,000-418,000-2,044,000-1,310,000-1,225,000-1,115,0001,344,0005,125,00011,209,0009,643,00019,458,00019,626,00018,536,00019,268,00034,295,0008,202,00014,887,00023,049,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
IPO date
Sep 22, 1999
Employees
23
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT